A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health (UM1 AI106701)
  • National Institutes of Health (UM1 AI068636)
  • National Institute of Allergy and Infectious Diseases (UM1 AI068634)
  • ACT Government

This publication has 31 references indexed in Scilit: